[Study on safety and immunogenicity of oral poliomyelitis attenuated live vaccine (human diploid cell)].
OBJECTIVE
To evaluate the safety and Immunogenicity of the Poliomyelitis vaccine (Human Diploid Cell) in > or =2 month-old children.


METHODS
A random, blind and control trial, 1200 healthy children of 2-5 months old in Jiangsu province were administered OPV (HDC) vaccine and control vaccines. The antibody was tested by neutralization test.


RESULTS
After 3 doses of the OPV (HDC) vaccine, the systemic reactions were mild. After 1 month of vaccination with 3 doses of the OPV (HDC) vaccine, the immune success rates of I, II, III type were 98.28%, 99.45%, and 95.71% respectively, the GMTs of I, II, III type in susceptible children were 1:1243.72, 1:234.38 and 1:273.10 respectively.


CONCLUSIONS
The OPV (HDC) vaccine was safe and immunogenicity for the children > or =2 months old.
Guo
Shao-Hong
SH
Beijing Tiantan Biological Products Co., Ltd., Beijing 100024, China.
Tao
Hong
H
Ying
Zhi-fang
ZF
D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology; D002681:China; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D011051:Poliomyelitis / Q000276:immunology / Q000517:prevention & control*; D011055:Poliovirus Vaccine, Oral / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
D000914:Antibodies, Viral; D011055:Poliovirus Vaccine, Oral; D014613:Vaccines, Attenuated